An investigation on behalf of investors in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares over potential wrongdoing at Regeneron Pharmaceuticals Inc was announced and NASDAQ:REGN stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 07/21/2015 -- An investigation for investors in NASDAQ:REGN shares was announced over potential breaches of fiduciary duties by certain officers and directors at Regeneron Pharmaceuticals.
Investors who purchased shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and currently hold any of those NASDAQ:REGN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundatiom or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Regeneron Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Regeneron Pharmaceuticals Inc reported that its annual Total Revenue rose from $2.1 million in 2013 to over $2.81 billion in 2014 and its Net Income declined from $424.36 million in 2013 to $348.07 million in 2014. Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) grew from $269.59 per share in December 2013 to as high as $552.98 per share on July 17, 2015.
Those who purchased shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego